4 Day Drafting Effective Pharmaceutical Patents Training Course: Explore the Latest Strategies and Gain Useful Insights and Practical Solutions to Your Drafting Issues (May 16-19, 2023)
February 06, 2023 04:08 ET
|
Research and Markets
Dublin, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The "Drafting Effective Pharmaceutical Patents Training Course" conference has been added to ResearchAndMarkets.com's offering. The highly complex area of...
The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Roche Ranked 1st Overall with Novo Nordisk in 2nd and Pfizer in 3rd
January 12, 2023 08:53 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Italy Edition: The Views of 103 Italian Patient Groups" report has been added to...
Patient Perspective of 151 German Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Ranking of 24 Companies
January 12, 2023 06:38 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Germany Edition - The Views of 151 German Patient Groups" report has been added...
Views of 258 Neurology Patient Groups on the Corporate Reputation of Pharma in 2022: Roche Ranked 1st, Novartis Ranked 2nd and Biogen Ranked 3rd
January 12, 2023 06:28 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Neurology Edition: The Views of 258 Neurology Patient Groups" report has been...
The Views of 300 Asian Patient Groups on the he Corporate Reputation of Pharma, 2021-2022: Overall Gilead Sciences Ranked 1st, Pfizer Ranked 2nd, and ViiV Healthcare Ranked 3rd
January 12, 2023 06:23 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Asia Edition - The Views of 300 Asian Patient Groups" report has been added to ...
The Views of 109 French Patient Groups on the Corporate Reputation of Pharma in 2021-2022: Amgen, Mylan, Eli Lilly, MSD, and Boehringer Ingelheim Witnessed the Biggest Rise in Rankings
January 12, 2023 06:18 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - France Edition - The Views of 109 French Patient Groups" report has been added to...
Corporate Reputation of Pharma Companies in Spain, 2020 vs 2021: ViiV Healthcare Ranked 1st, Janssen Ranked 2nd, Gilead Sciences Ranked 3rd
January 09, 2023 08:48 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Spain Edition: The Views of 154 Spanish Patient Groups" report has been added to...
Autoimmune Patient Perspective on the Corporate Reputation of Pharma Companies, 2021-2022: Focus on Innovation and Treatments, COVID-19, & Pricing and Access to Medicines
January 09, 2023 08:28 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Autoimmune Edition - The Views of 293 Patient Groups (138 of these respondent...
Patient Perspective of the Corporate Reputation of Pharma in 2021-2022: Focus on Chiesi Farmaceutici, AbbVie, Bayer, Eli Lilly, GSK, Merck, Mylan, Novartis, Pfizer, Roche, Sanofi, Teva Among Others
January 09, 2023 08:23 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups"...
The Corporate Reputation of Pharma Companies in Canada, 2021-2022: AbbVie, Roche, BMS, Sanofi, Pfizer, Merck, Bayer and Amgen Made the Biggest Rises
January 09, 2023 08:18 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added...